377 related articles for article (PubMed ID: 24372512)
21. Chromosome 20 deletions in myelodysplastic syndromes and Philadelphia-chromosome-negative myeloproliferative disorders: characterization by molecular cytogenetics of commonly deleted and retained regions.
Douet-Guilbert N; Basinko A; Morel F; Le Bris MJ; Ugo V; Morice P; Berthou C; De Braekeleer M
Ann Hematol; 2008 Jul; 87(7):537-44. PubMed ID: 18350294
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
23. Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.
Shiseki M; Ishii M; Okada M; Ohwashi M; Wang YH; Osanai S; Yoshinaga K; Mori N; Motoji T; Tanaka J
Leuk Res; 2019 Sep; 84():106175. PubMed ID: 31299412
[TBL] [Abstract][Full Text] [Related]
24. FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).
Makishima H; Rataul M; Gondek LP; Huh J; Cook JR; Theil KS; Sekeres MA; Kuczkowski E; O'Keefe C; Maciejewski JP
Leuk Res; 2010 Apr; 34(4):447-53. PubMed ID: 19758696
[TBL] [Abstract][Full Text] [Related]
25. [Study on prognostic significances of different cytogenetic risk categories in patients with primary myelodysplastic syndromes].
Qu SQ; Liu XP; Xu ZF; Zhang Y; Qin TJ; Zhang TJ; Cui R; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):819-24. PubMed ID: 22339954
[TBL] [Abstract][Full Text] [Related]
26. Fluorescence in situ hybridization characterization of ider(20q) in myelodysplastic syndrome.
Douet-Guilbert N; Laï JL; Basinko A; Gueganic N; Andrieux J; Pollet B; Plantier I; Delattre C; Crépin O; Corm S; Le Bris MJ; Morel F; De Braekeleer M
Br J Haematol; 2008 Dec; 143(5):716-20. PubMed ID: 19036015
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes.
Kawankar N; Jijina F; Ghosh K; Vundinti BR
Cancer Epidemiol; 2011 Aug; 35(4):e1-5. PubMed ID: 21193364
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
[TBL] [Abstract][Full Text] [Related]
30. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
31. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
33. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
34. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
[TBL] [Abstract][Full Text] [Related]
35. [Clinical and molecular cytogenetic features of myeloid diseases characterized by i(20q-): a study of seven cases].
Li TY; Xue YQ; Wu YF; Pan JL; Liu DD; Gong SL
Zhonghua Yi Xue Za Zhi; 2004 May; 84(9):732-5. PubMed ID: 15200909
[TBL] [Abstract][Full Text] [Related]
36. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
[TBL] [Abstract][Full Text] [Related]
37. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.
Giagounidis AA; Germing U; Haase S; Hildebrandt B; Schlegelberger B; Schoch C; Wilkens L; Heinsch M; Willems H; Aivado M; Aul C
Leukemia; 2004 Jan; 18(1):113-9. PubMed ID: 14586479
[TBL] [Abstract][Full Text] [Related]
38. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.
Steensma DP; List AF
Mayo Clin Proc; 2005 May; 80(5):681-98. PubMed ID: 15887439
[TBL] [Abstract][Full Text] [Related]
39. Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications.
Panani AD; Roussos C
Cancer Lett; 2006 Apr; 235(2):177-90. PubMed ID: 15935553
[TBL] [Abstract][Full Text] [Related]
40. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies.
Okada M; Suto Y; Hirai M; Shiseki M; Usami A; Okajima K; Teramura M; Mori N; Motoji T
Cancer Genet; 2012; 205(1-2):18-24. PubMed ID: 22429594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
